Illumina Acquires BlueGnome, Leading Provider of Cytogenetics and In Vitro Fertilization Screening Solutions

  Illumina Acquires BlueGnome, Leading Provider of Cytogenetics and In Vitro
  Fertilization Screening Solutions

   Acquisition Supports Illumina Goals in Diagnostics, Enhances Position in
                        Reproductive Health and Cancer

Business Wire

SAN DIEGO -- September 19, 2012

Illumina, Inc. (NASDAQ:ILMN) today announced that it has acquired Cambridge,
U.K.-based BlueGnome Ltd. for an undisclosed sum. BlueGnome, now a wholly
owned subsidiary of Illumina, is a leading provider of solutions for the
screening of genetic abnormalities associated with developmental delay,
cancer, and infertility.

“The BlueGnome acquisition supports Illumina’s goal to be the leader in
genomic-based diagnostics and enhances the company’s ability to establish
integrated solutions in reproductive health and cancer,” said Jay Flatley,
President and CEO of Illumina. “BlueGnome is the leader in the rapidly growing
IVF market and is well-known for their software and comprehensive assay

“By joining forces with Illumina, we will be able to leverage the industry’s
leading microarray and sequencing platforms for our next generation products,”
said Nick Haan, President and CEO of BlueGnome. “The throughput and data
quality of Illumina’s sequencers enable us to consider revolutionary new
approaches to genetic testing.”

In collaboration with some of the world’s leading in vitro fertilization (IVF)
centers, BlueGnome developed 24sure™, a preimplantation genetic screening
(PGS) test for counting the chromosomes in a single human cell – a test that
holds enormous promise for increasing IVF success rates. Clinical data has
shown that PGS greatly improves IVF success, increasing pregnancy rates for
women and reducing miscarriages.

BlueGnome’s offerings also include CytoChip, a powerful test for the
investigation of genetic abnormalities mainly associated with developmental
delay or with complex leukemias. CytoChip is used by more than 200 labs across
40 countries worldwide as a first-line cytogenetic test, replacing traditional
G-band karyotyping.

The company’s founders, Nick Haan and Graham Snudden, will continue to lead
BlueGnome which will report to Greg Heath, SVP and General Manager of
Illumina’s Diagnostics business. In addition to its headquarters in Cambridge,
England, BlueGnome has offices in Fairfax, Virginia and Singapore.

Added Greg Heath, “Our technologies are rapidly moving towards clinical
applications that can make dramatic and immediate impacts on people’s lives,
and the BlueGnome acquisition is an excellent fit with Illumina’s overall
genomic solutions and goals. We are very excited to welcome this talented team
to Illumina.”

About Illumina

Illumina ( is a leading developer, manufacturer, and marketer
of life science tools and integrated systems for the analysis of genetic
variation and function. We provide innovative sequencing and array-based
solutions for genotyping, copy number variation analysis, methylation studies,
gene expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products accelerate
genetic analysis research and its application, paving the way for molecular
medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release may contain forward looking statements that involve risks and
uncertainties. Important factors that could cause actual results to differ
materially from those in any forward-looking statements are detailed in our
filings with the Securities and Exchange Commission, including our most recent
filings on Forms 10-K and 10-Q, or in information disclosed in public
conference calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date of this


Illumina, Inc.
Scott Dawson
Jennifer Temple
Press spacebar to pause and continue. Press esc to stop.